BridgeBio Oncology Therap... (BBOT)
NASDAQ: BBOT
· Real-Time Price · USD
10.11
-0.90 (-8.17%)
At close: Sep 09, 2025, 3:59 PM
10.43
3.20%
After-hours: Sep 09, 2025, 07:37 PM EDT
Company Description
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors.
Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways.
The company recently went public through a business combination with Helix Acquisition Corp.
II, raising approximately $450 million to advance clinical development.
The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.
BridgeBio Oncology Therapeutics Inc.
| Country | United States |
| IPO Date | Aug 12, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | n/a |
| CEO | Eli M. Wallace |
Contact Details
Address: 256 E. Grand Avenue No city data available, United States | |
| Website | n/a |
Stock Details
| Ticker Symbol | BBOT |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US1079241022 |
| Employer ID | - |
| SIC Code | n/a |